<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140400</url>
  </required_header>
  <id_info>
    <org_study_id>G-9803</org_study_id>
    <nct_id>NCT00140400</nct_id>
  </id_info>
  <brief_title>Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer</brief_title>
  <official_title>Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Genesys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Genesys</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of a prime-boost dose
      schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine
      (Allogeneic Prostate GVAX®) as measured by standard toxicity evaluation, changes in PSA, and
      tumor responses. Additional objectives are to measure the time to PSA and/or clinical disease
      progression as well as local and systemic immune responses to the vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <completion_date>January 2001</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy allogeneic GM-CSF secreting cellular vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of adenocarcinoma prostate cancer

          -  Prostate cancer deemed to be unresponsive or refractory to hormone therapy

          -  An ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer

          -  Previous chemotherapy, biological or immunotherapy for cancer

          -  Previous gene therapy for cancer

          -  Significant cancer related pain
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>August 30, 2005</last_update_submitted>
  <last_update_submitted_qc>August 30, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2005</last_update_posted>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Advanced prostate cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Hormone-refractory</keyword>
  <keyword>GVAX</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Allogeneic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

